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Objective: To investigate the mechanism of antibacterial activity of luteolin (LUT)
against methicillin-resistant Staphylococcus aureus (MRSA).
Methods: The mechanism of anti-MRSA activity of LUT was analyzed by the viability
assay in membrane permeabilizing agent, ATPase inhibitors, and peptidoglycan (PGN)
derived from Staphylococcus aureus (S. aureus). Also, transmission electron microscopy
was used to monitor survival characteristics and changes in S. aureus morphology.
Results: Compared to the LUT alone, the optical density of suspensions treated with the
combination of 125 mg/mL Tris and 250 mg/mL N,N0-dicyclohexylcarbodiimide were
reduced to 60% and 46% of the control, respectively. PGN (15.6 mg/mL) gradually
impeded the activity of LUT, and PGN (62.5 mg/mL) completely blocked the activity of
LUT on S. aureus.
Conclusions: Increased susceptibility to LUT with the Tris-dicyclohexylcarbodiimide
combinations is evident in all tested MRSA isolates. The results indicate LUT synergy
in increasing cytoplasmic membrane permeability and inhibiting ATPase. S. aureus PGN
directly blocks the antibacterial activity of LUT, suggesting the direct binding of LUT
with PGN. These ﬁndings may be validated for the development of antibacterial agent for
low MRSA resistance.1. Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) was
ﬁrst reported in 1961, soon after the introduction of methicillin
into clinical use. MRSA is resistant to most b-lactam antibiotics
including penicillins and cephalosporins [1]. MRSA accounts fornearly 70 percent of Staphylococcus aureus (S. aureus)
infections, and is the main cause of community-acquired and
healthcare-associated infections [2]. The mechanisms of bacterial
resistance against antibiotics are inactivation of antibiotics by
enzymes, change in the target site, change of membrane
permeability, and antibiotic efﬂux out of cells [3,4]. Therefore,
alternative therapeutic strategies involving effective
antimicrobial agents that minimize bacterial resistance to
antibiotics are needed.
Luteolin (LUT), a well-known ﬂavonoid polyphenolic com-
pound (Figure 1), is found in many plant groups including
Bryophyta, Pteridophyta, Pinophyta, and Magnoliophyta. LUT
has diverse biological beneﬁts that include cardioprotection,
antioxidantion, anti-inﬂammation, anti-cancer, and antimicrobial
effects [5–9]. Qio et al. reported the impact of LUT on the alpha-rticle under the CC BY-NC-ND license (http://
Figure 1. Structure of LUT.
Figure 2. Effect of membrane-permeabilizing agent Tris and ATPase-
inhibitor N,N0-DCCD on susceptibility of S. aureus (ATCC 33591) to LUT.
The viability of bacteria was determined spectrophotometrically (optical
density at 600 nm, OD 600 nm) after incubation for 36 h with 3.9 mg/mL
LUT with 125 mg/mL Tris and 250 mg/mL DCCD. The data was the
average of three independent experiments. *P < 0.01 as compared to LUT
alone, were determined.
Table 1
MIC of LUT against two strains of S. aureus used in this study.
Strains MIC (mg/mL)
LUT Oxacillin
MSSA (ATCC 25923) 62.5 62.5
MRSA (ATCC 33591) 62.5 500.0
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toxin [10]. In the present study, we investigated the anti-MRSA
activity of LUT on the membrane-binding agent and ATPase-
inhibiting agents. We also conﬁrmed that binding effect of
LUT on the bacterial cell wall. Bacterial ultrastructural changes
following treatment with LUT were assessed by transmission
electron microscopy (TEM).
2. Materials and methods
2.1. Reagents
N,N0-dicyclohexylcarbodiimide (DCCD) and lipopolysac-
charide (LPS) were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Mueller-Hinton broth (MHB) was purchased from
Difco (Baltimore, MD, USA). Tris-(hydroxymethyl) amino-
methane (Tris) was obtained from AMRESCO (San Francisco,
CA, USA). Peptidoglycan (PGN) was purchased fromFluka
(Basel, Switzerland).
2.2. Bacterial strains and growth conditions
S. aureus ATCC 33591 (methicillin-resistant strain) and
S. aureus ATCC 25923 (methicillin-susceptible strain) were
stored in 30%glycerol and frozen at −70 C. They were cultured
in MHA and MHB, and incubated at 37 C for 24 h for each
experiment.
2.3. Minimum inhibitory concentration (MIC)
MIC was determined using the broth micro dilution method
according to the Clinical and Laboratory Standards Institute
2006 guideline [11]. LUT was diluted in MHB in 96-well plate
(0.5% w/v stock concentration). Preparation of the
microorganism suspension was prepared by growing S. aureus
in broth for 24 h, and adjusting the suspensions to 0.5
McFarland standard turbidity (approximately 1.5 × 108 CFU/
mL). The ﬁnal inoculum was adjusted to 1.5 × 106 CFU/mL.
Inoculated broth in wells was incubated at 37 C for 18 h. At
the end of each incubation period, turbidity indicated that
bacterial growth had not been inhibited by the concentration
of antimicrobial agent in the medium. MIC was deﬁned at the
lowest concentration of antibiotics and LUT that inhibited
growth.
2.4. Effect of LUT on membrane-permeabilizing agent
or ATPase inhibitors
To elucidate whether the antibacterial activity of LUT was
associated with either altered membrane permeability or ATPsynthase inhibit, the antibacterial activity of LUT was examined
in the presence of membrane-permeabilizing agent, Tris and
adenosine triphosphatase (ATPase)-inhibiting agents, N,N-
DCCD respectively. Tris was used to increase membrane
permeability of cell membranes [1]. DCCD, a metabolic inhibitor
that could decrease ATP levels by disrupting electrochemical
proton gradients in a bacterial environment, was used as an
inhibitor of ATPase [12]. The effect of LUT on the membrane-
permeabilizing agent (125 mg/mL Tris) or ATPase inhibitor
(250 mg/mL DCCD) was determined.
2.5. Effect of PGN on LUT activity
To determine the activity of PGN in the presence of LUT, a
LUT + PGN combination assay was performed [13]. This assay
indicated whether LUT bound to PGN, the major constituent
of the S. aureus cell wall. LUT (31.25 mg/mL) was added to
PGN by serial dilution. LPS, a constituent of the outer
membrane of Gram-negative bacteria [14], was used as
negative control.
Figure 3. Direct binding of LUT with PGN in cell wall of S. aureus
(ATCC 25923).
PGN was added to MHB containing LUT. LPS was used as a control.
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MRSA exponential-phase cultures were prepared by diluting
cultures into MHB overnight, which was continued at 37 C
until the cultures reached the mid-logarithmic phase of growth.
MHB-grown exponential-phase MRSA was treated with 1/2
MIC and the MIC of LUT for 30 min. Following the treatment,
2 mL of the culture was collected by centrifugation at 10000 g
for 10 min. After removal of the supernatant, pellets were ﬁxed
with modiﬁed Karnovsky's ﬁxative. The specimens were
examined with an energy-ﬁltering LIBRA 120 TEM (CarlZeiss,
Oberkochen, Germany) at an accelerating voltage of 120 kV.
Transmitted electron signals were recorded using anUl-
trascan4000 SP 4 k × 4 k slow-scan charge-coupled device
camera (Gatan, Pleasanton, CA, USA) attached to the electron
microscope.Figure 4. TEM images of MRSA (ATCC 33591) after 24 h of LUT treatmen
(A) MRSA in the untreated control appeared to have intact membrane. (B)
hampered membrane integrity and caused membrane damage. (C) MRSA treatm
disruption and separated cell.2.7. Statistical analyses
All experiments were performed more than three times. Data
from the experiments are presented as the mean ± standard error
of the mean. Statistical analyses were performed using one-way
analysis of variance followed by Dunnett's t test (SPSS software
version 19.0; IBM SPSS, Armonk, NY, USA). P < 0.01 was
considered statistically signiﬁcant difference.
3. Results
3.1. Potentiated effects of LUT by Tris and DCCD
MIC values of LUT against two strains of S. aureus were
presented in Table 1. Compared to the optical density at 600 nm
(OD600) value of LUT alone (3.9 g/mL), the OD600 of suspen-
sions treated with the combination of 125 mg/mL Tris was
reduced to 60%.Bacterial viability in the presence of LUT with
250 mg/mL DCCD, a metabolic inhibitor, as reduced to 46%
compared to LUT alone (3.9 g/mL) (Figure 2).
3.2. Binding of LUT and PGN
The binding of LUT with PGN was conﬁrmed by the addi-
tion of PGN (0.0–62.5 mg/mL) derived from S. aureus into
MHB containing LUT. As shown in Figure 3, LUT (31.25 mg/
mL) inhibited S. aureus growth by over 25%. A 62.5 mg/mL
concentration of PGN disturbed the activity of LUT and 15.6 mg/
mL concentration of PGN impeded the activity of LUT on
S. aureus, while 62.5 mg/mL PGN completely blocked the
antibacterial activity of LUT.
3.3. TEM
Antibiotic drugs induced other cellular changes such as
separation of cytoplasmic contents [15]. The antibacterial
activity of LUT on MRSA might be due to the ability of
LUT to disrupt the cell wall of MRSA. LUT induced
membrane disruption and cell lysis. LUT-free cultured cells
had a normal morphology of S. aureus with distinct septa and
smooth surfaces (Figure 4A). Cells treated with LUT
(31.25 mg/mL) appeared to have damaged cytoplasmic mem-
brane and had a rougher surface (Figure 4B). MRSA cellst.
MRSA treatment with 1/2 MIC of LUT (31.25 mg/mL). Arrows indicate
ent with MIC LUT (62.5 mg/mL). Arrows indicate cytoplasmic membrane
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intracellular contents (Figure 4C).
4. Discussion
There is a clear need for development of new antibiotic that
are widely effective against multidrug-resistant pathogens. We
examined the effects of the membrane permeabilizing agent and
ATP-binding cassette (ABC) transporter inhibiting agent on
antibacterial activity of LUT. Most bacteria produce ABC
transporter that is an essential uptake system for amino acids in
the bacterial membrane. This is a determinant of bacterial
antibiotic resistance [15–17]. ABC transporters have ATP-
dependent transporting activity; DCCD inhibits the H+ trans-
location activity of the F0 domain of F0F1-ATPase [14]. In
MRSA, LUT showed synergistic activity by increasing
cytoplasmic membrane permeability and inhibiting ATPase.
Gram-positive bacteria including S. aureus contain numerous
layers (up to 30) of PGN. In S. aureus and other Gram-positive
and Gram-negative bacteria, PGN is essential in osmotic pro-
tection and cell division [18]. Wall teichoic acids of S. aureus are
anionic glycopolymers cross-linked to the thick PGN network,
serving as a primer for cell wall biosynthesis [14,15]. The direct
binding of PGN and LUT completely interrupts LUT-induced
damage of the bacterial cell wall. The focus of the present
study was on the development of natural antimicrobial agents to
directly address the multidrug resistant of S. aureus. These
ﬁndings can be important indication in study on mechanism of
antimicrobial activity against MRSA in vitro. Further, in vivo
experiments are needed for clinical application in MRSA-
infection.
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